Development of Anaplastic Lymphoma Kinase (ALK) Inhibitors and Molecular Diagnosis in ALK Rearrangement-Positive Lung Cancer
OncoTargets and Therapy - New Zealand
doi 10.2147/ott.s38868
Full Text
Open PDFAbstract
Available in full text
Date
March 1, 2014
Authors
Publisher
Informa UK Limited